Open Access Open Badges Review

The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program

James M Balwit1, Patrick Hwu2, Walter J Urba3 and Francesco M Marincola14*

Author Affiliations

1 Society for Immunotherapy of Cancer, Milwaukee, WI, USA

2 Department of Melanoma Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA

3 Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA

4 Infectious Disease and Immunogenetics Section (IDIS), Dept. of Translation Medicine, Clinical Center, and Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA

For all author emails, please log on.

Journal of Translational Medicine 2011, 9:18  doi:10.1186/1479-5876-9-18

Published: 31 January 2011


The Society for Immunotherapy of Cancer, SITC (formerly the International Society for Biological Therapy of Cancer, iSBTc), aims to improve cancer patient outcomes by advancing the science, development and application of biological therapy and immunotherapy. The society and its educational programs have become premier destinations for interaction and innovation in the cancer biologics community. For over a decade, the society has offered the Primer on Tumor Immunology and Biological Therapy of Cancerâ„¢ in conjunction with its Annual Scientific Meeting. This report summarizes the 2010 Primer that took place October 1, 2010 in Washington, D.C. as part of the educational offerings associated with the society's 25th anniversary. The target audience was basic and clinical investigators from academia, industry and regulatory agencies, and included clinicians, post-doctoral fellows, students, and allied health professionals. Attendees were provided a review of basic immunology and educated on the current status and most recent advances in tumor immunology and clinical/translational caner immunology. Ten prominent investigators presented on the following topics: innate immunity and inflammation; an overview of adaptive immunity; dendritic cells; tumor microenvironment; regulatory immune cells; immune monitoring; cytokines in cancer immunotherapy; immune modulating antibodies; cancer vaccines; and adoptive T cell therapy. Presentation slides, a Primer webinar and additional program information are available online on the society's website.